Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Operating Leases (2022 - 2026)

HeartSciences filings provide 5 years of Operating Leases readings, the most recent being $211917.0 for Q1 2026.

  • On a quarterly basis, Operating Leases fell 38.72% to $211917.0 in Q1 2026 year-over-year; TTM through Jan 2026 was $211917.0, a 38.72% decrease, with the full-year FY2025 number at $314527.0, down 27.54% from a year prior.
  • Operating Leases hit $211917.0 in Q1 2026 for HeartSciences, down from $247263.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $583016.0 in Q1 2023 to a low of $211917.0 in Q1 2026.
  • Median Operating Leases over the past 5 years was $419894.0 (2024), compared with a mean of $410401.2.
  • Biggest five-year swings in Operating Leases: fell 11.35% in 2023 and later crashed 38.72% in 2026.
  • HeartSciences' Operating Leases stood at $549227.0 in 2022, then dropped by 11.35% to $486885.0 in 2023, then decreased by 22.72% to $376241.0 in 2024, then plummeted by 34.28% to $247263.0 in 2025, then fell by 14.29% to $211917.0 in 2026.
  • The last three reported values for Operating Leases were $211917.0 (Q1 2026), $247263.0 (Q4 2025), and $281570.0 (Q3 2025) per Business Quant data.